Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when NICE plans to publish the outcome of its assessment of the effectiveness of Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer.

In February 2021, the National Institute for Health and Care Excellence issued final guidance that recommends niraparib for use within the Cancer Drugs Fund (CDF) for the maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. Niraparib is now available to eligible National Health Service patients in England through the CDF in line with this recommendation.